Community

Advertising Opportunities

 Biotechnology Europe Programs

 Resources

Biotechnology Europe Community

Feedback

Contact

Biotechnology Europe Advantages

Advertising Opportunities on Biotechnology Europe

Sponsorship Opportunities on Biotechnology Europe

 

Post a Job on Biotechnology Europe

Post a Company Profile on Biotechnology Europe

Post a News on Biotechnology Europe

Post an Event on Biotechnology Europe

Post a Product on Biotechnology Europe

Post a Publication on Biotechnology Europe

Post a Technology on Biotechnology Europe

Post a Resume on Biotechnology Europe

Terms of Business

Imprint

Privacy Policy

FAQ

Subscribe Newsletter

 

Life Therapeutics  News

   

 

 

   
     

   
 
   
   
   
   
   
   
   
   
   
   
   
   
   
   
   
   

post your news I subscribe newsletter I contact us

 
 
     

 

2007 I

LFE Appoints New Director and Chairman of Board

13th February 2008 Sydney

 

Life Therapeutics (ASX: LFE) announces the appointment with immediate effect of Mr Michael Milne as a director of the company.

Mr Milne is an Australian resident and brings to the LFE Board significant corporate experience. Mr Milne is a Fellow of the Australian Institute of Company Directors.

LFE advises that for personal reasons Dr Jim Brown has decided to stand down as Chairman of the Board and will be replaced in his role with immediate effect by Mr Milne. Dr Brown will remain as a non-executive director of the LFE Board.

LFE also announces the resignation of Ms Rachel Freeman as Acting Company Secretary. As previously noted in an announcement dated 8 January 2008, Catherine Caradus from TMF Corporate Services (Aust) Pty Limited has been appointed as the Company Secretary.

 

About Life Therapeutics

 

Life Therapeutics is an international company that specializes in niche therapeutic hyperimmune products. It has 12 operational plasma collection centers and signed leases for a further 2 centers around the US. The Company has considerable experience recruiting and collecting hard to find hyperimmune plasma for IND studies and clinical trials.

 

Life Therapeutics has 480 employees, located in the United States and 12 plasma donor centers in seven American States. It has an established U.S. American Depositary Receipt (ADR) Level I program, which enables trading in Life Therapeutics shares by U.S. based investors. The company’s divisions are all headquartered in Atlanta, Georgia.

 

Life Sera collects both specialty plasma and normal source plasma, including Anti-D and Hepatitis B from a donor base of more than 5,000 in fourteen operational U.S. collection centers. The plasma is then sold to blood fractionators who process it into hyperimmune therapeutic products.

 

Life Diagnostics provides highly specific diagnostic tests for blood-clotting disorders and source plasma products for blood-borne diseases. Technologies include specialized blood coagulation tests to predict the risk of thrombosis and bleeding disorders. It also collects high-titer source plasma and serum used to make diagnostic kits.

 

For more information, visit www.life-therapeutics.com.

Enquiries: Email: info@life-therapeutics.com

TMF Corporate Services (Aust) Pty Ltd

Level 9

50 Park Street

Sydney, NSW 2000

Phone: (61) 2 8988 5808

 

 

 

 
 Life Therapeutics News   
27.11.2007 Board of Life Therapeutics Recommends New Terms of Agreement with Kedrion, Provides Corporate Update and Further Information on the Company’s Management  
   
04.10.2007 Life Therapeutics Announces Unsolicited Cash Offer of US$60 million for Plasma Collection Centres  
   
21.09.2007 Life Therapeutics Announces Unsolicited Cash Offer of US$50 million for Plasma Collection Centres  
   
18.09.2007 Life Therapeutics Announces Plan for Assets sale and Share Buyback  
   
   12.09.2007 Life Therapeutics Announces Senior Appointment and Provides Update on Operations and Kedrion Transaction  
   

  05.09.2007Life Therapeutics Appoints PwC to Provide Independent Valuation of Kedrion Transaction

 
   

  30.07.2007 Life Therapeutics Announces New Terms of Agreement with Kedrion 

 
   

   03.07.2007 Life Therapeutics to Re-Negotiate Terms of Agreement with Kedrion

 

    20.06.2007 Further Update on Status of Heads of Agreement with European Fractionator

 
   

    31.05.2007 Update on Status of Heads of Agreement with European Fractionator

 
   

 
 
 
Google
 
 
 
 I back I top I  

 

 

 

 

office@biotechnology-europe.com I website@biotechnology-europe.com I service@biotechnology-europe.com

 


 

Advertising Opportunities on Biotechnology Europe

Sponsorship Opportunities on Biotechnology Europe

About Biotechnology Europe

Post a Job on Biotechnology Europe

Post a Company Profile on Biotechnology Europe

Post a News on Biotechnology Europe

Post an Event on Biotechnology Europe

Post a Product on Biotechnology Europe

Post a Publication on Biotechnology Europe

Post a Technology on Biotechnology Europe

Post a Resume on Biotechnology Europe


 

Biotechnology Europe Your Partner in Bioscience and Business

  Central Internet Platform and Service Company For The Life Sciences in Europe

Imprint I Site map I Privacy Policy I Contact us I About us I Copyright BIOTECHNOLOGY WORLD  All rights reserved